<!DOCTYPE html>
<html>
  <head>
    <link rel="stylesheet" href="globals.css" />
    <link rel="stylesheet" href="style.css" />
  </head>
  <body>
    <div class="wireframe">
      <div class="div">
        <div class="overlap-group">
          <img class="asset" src="https://c.animaapp.com/To7l7eki/img/asset-13-300x-1.png" />
          <img class="asset-x" src="https://c.animaapp.com/To7l7eki/img/asset-10-300x-1.png" />
          <div class="rectangle"></div>
          <div class="rectangle-2"></div>
          <img class="img" src="https://c.animaapp.com/To7l7eki/img/asset-6-300x-1@2x.png" />
          <div class="text-wrapper">Instructions for Use</div>
          <div class="text-wrapper-2">Prescribing Information</div>
          <div class="text-wrapper-3">Health Care Setting Locator</div>
          <img class="asset-2" src="https://c.animaapp.com/To7l7eki/img/asset-7-300x-1@2x.png" />
          <div class="rectangle-3"></div>
          <div class="text-wrapper-4">LOGIN</div>
        </div>
        <div class="rectangle-4"></div>
        <div class="overlap">
          <div class="rectangle-5"></div>
          <p class="p">Contact the HEPZATO KIT REMS by calling 1-833-632-0457</p>
        </div>
        <p class="text-wrapper-5">What is the HEPZATO KITTM REMS?</p>
        <div class="overlap-2">
          <div class="text-wrapper-6">Health Care Setting Locator</div>
          <p class="text-wrapper-7">Find a certified treatment center near you</p>
        </div>
        <div class="text-wrapper-8">Reporting Adverse Events</div>
        <div class="overlap-3">
          <p class="a-risk-evaluation">
            A Risk Evaluation and Mitigation Strategy (REMS) is a program to manage known or potential serious risks
            associated with a drug product and is required by the Food and Drug Administration (FDA).&nbsp;&nbsp;<br /><br />The
            FDA has determined that a REMS is necessary to ensure that the benefits of HEPZATO KIT outweigh the risks of
            severe peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events
            associated with HEPZATO KIT.
          </p>
          <div class="rectangle-6"></div>
          <p class="healthcare-setting">
            <span class="span">Healthcare Setting must be certified in the</span>
            <span class="span"> HEPZATO KIT REMS Portal </span>
            <span class="span">in order to treat with the HEPZATO KIT.</span>
          </p>
          <div class="rectangle-7"></div>
          <div class="text-wrapper-9">Get Started</div>
          <img class="asset-3" src="https://c.animaapp.com/To7l7eki/img/asset-14-300x-1@2x.png" />
        </div>
        <p class="reporting-of">
          <span class="text-wrapper-10"
            >Reporting of suspected adverse events after administration of HEPZATO KIT therapy is vital for the
            continued monitoring of the risk/benefit balance of therapy.<br /><br />To report serious adverse events*
            including hemorrhage, hepatocellular injury, and thromboembolic events using the Severe
            Peri-Procedure-related Complications Adverse Events Documentation Form to Delcath Systems, Inc. via e-mail
            at
          </span>
          <span class="text-wrapper-11">coordinator@HEPZATOKITREMS.com<br /><br /></span>
          <span class="text-wrapper-10"
            >To report any other serious adverse events* to Delcath at 1-833-632-0458 or to or FDA at 1-800-FDA-1088 or
            â€¨</span
          >
          <span class="text-wrapper-11">www.fda.gov/medwatch</span>
        </p>
        <div class="text-wrapper-12">Have Questions?</div>
        <p class="severe-peri">
          <br />Severe peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic
          events may occur via hepatic intra-arterial administration of HEPZATO. <br /><br />Assess patients for these
          adverse reactions during and for at least <br />72 hours following administration of HEPZATO. HEPZATO is
          available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the HEPZATO
          KIT REMS. <br /><br />Myelosuppression with resulting severe infection, bleeding, or symptomatic anemia may
          occur with HEPZATO. Monitor hematologic laboratory parameters and delay additional cycles of HEPZATO therapy
          until blood counts have improved.
        </p>
        <p class="WARNING-SEVERE-PERI">
          <span class="text-wrapper-13">WARNING: SEVERE PERI-PROCEDURAL COMPLICATIONS, <br />MYELOSUPPRESSION </span>
          <span class="text-wrapper-13">&nbsp;</span>
        </p>
        <img class="asset-4" src="https://c.animaapp.com/To7l7eki/img/asset-15-300x-1.png" />
      </div>
    </div>
  </body>
</html>
